目的：探讨利培酮联合氯硝西泮与氟哌啶醇治疗精神分裂症患者急性激越症状的疗效和安全性。方法将69例伴急性激越症状的精神分裂症患者随机分为两组，研究组口服利培酮联合氯硝西泮治疗，对照组予以氟哌啶醇治疗，观察4周。于治疗前后采用阳性与阴性症状量表总分及兴奋因子分评定临床疗效，副反应量表评定不良反应。结果治疗后两组阳性与阴性症状量表总分及兴奋因子评分较治疗前持续下降（ P＜0．01），治疗4周末研究组显效率57．1％、有效率97．1％，对照组分别为50．0％、100％，两组比较差异均无显著性（χ2＝0．35、0．99，P＞0．05）。研究组不良反应发生率为37．1％、苯海索使用率为8．6％，对照组分别为64．7％、44．1％，研究组显著低于对照组（χ2＝5．24、11．30，P＜0．05或0．01）。结论利培酮联合氯硝西泮能够快速有效控制精神分裂症急性激越症状，疗效与氟哌啶醇相当，但安全性更高，具有长程治疗优势，有利于患者的连续性治疗。、Objective To explore the efficacy and safety of risperidone combined with clonazepam vs .halo‐peridol in schizophrenia with acute agitated symptoms .Methods Sixty‐nine schizophrenics with acute agi‐tated symptoms were randomly divided into two groups ,research group was treated with risperidone plus clonazepam orally and control group with haloperidol for 4 weeks .Efficacies were assessed with the total and excitation score of the Positive and Negative Syndrome Scale (PANSS) before and after treatment and adverse reactions with the Treatment Emergent Symptom Scale (TESS) .Results After treatment the to‐tal and excitation scores of the PANSS of both groups lowered continuously compared with pretreatment (P<0 .01) ,at the end of the 4th week obvious effective and effective rate were respectively 57 .1% and 97 .1% in research and 50 .0% and 100% in control group ,which showed no significant differences (χ2 =0 .35 ,0 .99 ;P>0 .05) .The incidence of adverse reactions was 37 .1% and benzhexol use rate 8 .6% in re‐search and 64 .7% and 44 .1% in control group ,the former was significantly lower than the latter (χ2 =5 .24 ,11 .30 ;P<0 .05 or 0 .01) .Conclusion Risperidone combined with clonazepam could rapidly and ef‐fectively control schizophrenic acute agitated symptoms ,has an equivalent effect to haloperidol ,higher safety and a long‐term treatment advantage ,and is beneficial to patients’ continuous treatment .